Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Matagne

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Epilepsia|April 26, 2013
Lacosamide treatment following status epilepticus attenuates neuronal cell loss and alterations in hippocampal neurogenesis in a rat electrical status epilepticus modelThomas Licko, Natalie Seeger, Christina Zellinger, et al.
Epilepsy Research|May 4, 2004
Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticusAndrey M Mazarati, Roger Baldwin, Henrik Klitgaard, et al.
Epilepsia|June 10, 2017
Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticusJerome Niquet, Lucie Suchomelova, Kerry Thompson, et al.
Epilepsia|August 30, 2017
Brivaracetam does not modulate ionotropic channels activated by glutamate, γ-aminobutyric acid, and glycine in hippocampal neuronsIsabelle Niespodziany, Jean-Michel Rigo, Gustave Moonen, et al.
Epilepsia|March 31, 2015
Anti-ictogenic and antiepileptogenic properties of brivaracetam in mature and immature ratsNina Dupuis, Alain Matagne, Ludovicus Staelens, et al.
European Journal of Pharmacology|April 23, 2009
Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsyAlain Matagne, Doru-Georg Margineanu, Heidrun Potschka, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 3, 2007
Seletracetam (UCB 44212)Barbara Bennett, Alain Matagne, Philippe Michel, et al.
Biochemical and Biophysical Research Communications|August 12, 2008
Visualization of SV2A conformations in situ by the use of Protein TomographyBerkley A Lynch, Alain Matagne, Annika Brännström, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 2004
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetamBerkley A Lynch, Nathalie Lambeng, Karl Nocka, et al.
Neuropharmacology|January 22, 2008
SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsyRafal M Kaminski, Alain Matagne, Karine Leclercq, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Epilepsia|April 26, 2013
Lacosamide treatment following status epilepticus attenuates neuronal cell loss and alterations in hippocampal neurogenesis in a rat electrical status epilepticus modelThomas Licko, Natalie Seeger, Christina Zellinger, et al.
Epilepsy Research|May 4, 2004
Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticusAndrey M Mazarati, Roger Baldwin, Henrik Klitgaard, et al.
Epilepsia|June 10, 2017
Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticusJerome Niquet, Lucie Suchomelova, Kerry Thompson, et al.
Epilepsia|August 30, 2017
Brivaracetam does not modulate ionotropic channels activated by glutamate, γ-aminobutyric acid, and glycine in hippocampal neuronsIsabelle Niespodziany, Jean-Michel Rigo, Gustave Moonen, et al.
Epilepsia|March 31, 2015
Anti-ictogenic and antiepileptogenic properties of brivaracetam in mature and immature ratsNina Dupuis, Alain Matagne, Ludovicus Staelens, et al.
European Journal of Pharmacology|April 23, 2009
Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsyAlain Matagne, Doru-Georg Margineanu, Heidrun Potschka, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 3, 2007
Seletracetam (UCB 44212)Barbara Bennett, Alain Matagne, Philippe Michel, et al.
Biochemical and Biophysical Research Communications|August 12, 2008
Visualization of SV2A conformations in situ by the use of Protein TomographyBerkley A Lynch, Alain Matagne, Annika Brännström, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 2004
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetamBerkley A Lynch, Nathalie Lambeng, Karl Nocka, et al.
Neuropharmacology|January 22, 2008
SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsyRafal M Kaminski, Alain Matagne, Karine Leclercq, et al.
Pageof 3